证券代码：301622 股票简称：英思特 包头市英思特稀磁新材料股份有限公司 投资者关系活动记录表 3、问：公司越南工厂建设情况？ 答：越南工厂于 2023 年设立并于 2024 年通过相关供应商 供应链认证，公司建设越南工厂主要原因是开发更多的其他海 外知名消费电子客户，目前生产经营良好，产能根据订单需求 及时进行调整。 4、问：机器人领域对于磁材技术认证要求？公司在人形 机器人这方面的进展如何？ 答：机器人领域磁材的认证及相关技术要求同电机类似， 根据终端不同应用场景，其要求也不尽相同。一般来说，产品 需满足材料性能如高剩磁、高矫顽力、耐高温、耐腐蚀等，同 时还要拥有严格的质量管理体系，产品需经过多次实验才能应 用到最终机型上。公司在机器人领域已经建立相关课题，拥有 了一定的技术储备和材料研究经验，目前已给人形机器人电机 的客户送样。由于人形机器人市场化是一个逐步推进的过程， 受到技术成熟度、生产成本、市场需求等多重因素影响，当前 人形机器人在国内的发展正处于从技术突破向规模化量产过 渡的关键阶段，相信未来随着供应链上下游技术水平不断提 升，伴随其他配套产品技术的发展进步，人形机器人的产量也 会逐渐释放。 ...

证券代码：301622 证券简称：英思特 公告编号：2025-010 一、重要提示 所有董事均已出席了审议本报告的董事会会议。 容诚会计师事务所（特殊普通合伙）对本年度公司财务报告的审计意见为：标准的无保留意见。 本报告期会计师事务所变更情况：公司本年度会计师事务所由变更为容诚会计师事务所（特殊普通合 伙）。 非标准审计意见提示 □适用 √不适用 公司上市时未盈利且目前未实现盈利 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 √适用 □不适用 公司经本次董事会审议通过的利润分配预案为：以115,931,880股为基数，向全体股东每10股派发现金红 利1.20元（含税），送红股0股（含税），以资本公积金向全体股东每10股转增0股。 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者 应当到证监会指定媒体仔细阅读年度报告全文。 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 二、公司基本情况 1、公司简介 ■ 2、报告期主要业务或产品简介 （1）主营业务及其产品情况 公司是一家主要从事稀土永磁材料应用器件研发、生产和销售的高新技术企业。 ...

Group 1 - Company Instech reported a net profit of 177 million yuan for 2024, a year-on-year increase of 28.15%, with a proposed cash dividend of 1.20 yuan per 10 shares [1] - Instech achieved an operating revenue of 1.185 billion yuan in 2024, representing a year-on-year growth of 24.45% [1] - The company specializes in the research, production, and sales of rare earth permanent magnet materials and applications [2] Group 2 - Company Junda reported a net loss of 106 million yuan for Q1 2025, transitioning from profit to loss, with a year-on-year revenue decline of 49.52% [3] - Junda's operating revenue for Q1 2025 was 1.875 billion yuan [3] - The company focuses on the research, production, and sales of photovoltaic cell products [4] Group 3 - Company Annada reported a net loss of 10.26 million yuan for Q1 2025, with a year-on-year revenue increase of 1.44% [5] - Annada's operating revenue for Q1 2025 was 473 million yuan [5] - The company specializes in titanium dioxide and iron phosphate products [6] Group 4 - Company Jiuzhou Pharmaceutical reported a net profit of 250 million yuan for Q1 2025, a year-on-year increase of 5.68% [7] - Jiuzhou's operating revenue for Q1 2025 was 1.49 billion yuan, reflecting a year-on-year growth of 0.98% [7] - The company provides custom research and production services for pharmaceutical companies and research institutions [8] Group 5 - Company Yitong Century won a 1.48 billion yuan contract for a 5G comprehensive maintenance project with Guangdong Unicom [9] - The project will enhance the company's business volume and expansion in Guangdong [9] - Yitong Century specializes in communication network technology services and solutions [10] Group 6 - Company Rijiu Optoelectronics reported a net profit of 67.47 million yuan for 2024, a year-on-year increase of 506.9%, with a proposed cash dividend of 2.00 yuan per 10 shares [10] - Rijiu's operating revenue for 2024 was 583 million yuan, representing a year-on-year growth of 22% [10] - The company focuses on the research, production, and sales of touch display application materials [11] Group 7 - Company Ruotong reported a net profit of 95.98 million yuan for 2024, a year-on-year increase of 0.91%, with a proposed cash dividend of 2.00 yuan per 10 shares [12] - Ruotong's operating revenue for 2024 was 408 million yuan, reflecting a year-on-year growth of 7.54% [12] - The company specializes in drilling and completion equipment for oil and gas [13] Group 8 - Company Shuangxiang reported a net profit of 472 million yuan for 2024, a year-on-year increase of 754.84%, with a proposed cash dividend of 1.50 yuan per 10 shares [14] - Shuangxiang's operating revenue for 2024 was 2.29 billion yuan, representing a year-on-year growth of 51.55% [14] - The company focuses on synthetic leather and optical-grade PMMA products [15] Group 9 - Company Xinfang Pharmaceutical reported a net profit of 101 million yuan for 2024, a year-on-year decrease of 64.70%, with a proposed cash dividend of 0.30 yuan per 10 shares [16] - Xinfang's operating revenue for 2024 was 6.032 billion yuan, reflecting a year-on-year decline of 6.63% [16] - The company is involved in medical services, pharmaceutical distribution, and manufacturing [17] Group 10 - Company Dongxing Medical reported a net profit of 97.42 million yuan for 2024, a year-on-year increase of 0.21%, with a proposed cash dividend of 6.00 yuan per 10 shares [18] - Dongxing's operating revenue for 2024 was 435 million yuan, reflecting a year-on-year growth of 0.40% [18] - The company specializes in surgical medical devices [19] Group 11 - Company Wuzhou Special Paper reported a net profit of 64.68 million yuan for Q1 2025, a year-on-year decrease of 51.56%, with an operating revenue of 1.989 billion yuan [20] - Wuzhou's operating revenue for Q1 2025 increased by 15.21% [20] - The company focuses on the research, production, and sales of mechanism paper and pulp [21] Group 12 - Company Jinrui Mining expects a net profit of 15.28 million yuan for Q1 2025, a year-on-year increase of 617.40% [22] - The company specializes in the production and sales of strontium salt products [23] Group 13 - Company Youyan New Materials expects a net profit of 60 million to 75 million yuan for Q1 2025, a year-on-year increase of 13076% to 16370% [24] - The company focuses on electronic films, precious metal materials, and rare earth materials [25] Group 14 - Company Guoli expects a net profit of 11 million to 13 million yuan for Q1 2025, a year-on-year increase of 164.38% to 212.45% [26] - The company specializes in urban infrastructure design, construction, and investment [27] Group 15 - Company Shenzhen Airport reported a passenger throughput of 5.5422 million in March, a year-on-year increase of 8.70% [28] - The airport's cargo throughput was 171,900 tons, reflecting a year-on-year growth of 14.51% [28] - The company is involved in aviation and related non-aviation businesses [29] Group 16 - Company Shenghui Integration reported an order balance of 2.117 billion yuan as of March 31, 2025, a year-on-year increase of 11.89% [30] - The company provides cleanroom engineering and electromechanical engineering services [31] Group 17 - Company Chengyi Pharmaceutical received a drug registration certificate for Mercaptopurine tablets [32] - The drug is applicable for various diseases including choriocarcinoma and acute lymphoblastic leukemia [32] Group 18 - Company Enhua Pharmaceutical initiated Phase I clinical trials for NH280105 capsules, targeting Alzheimer's disease [33] - The trial aims to assess the safety and pharmacokinetics of the drug [33] Group 19 - Company Lingang Steel proposed a share buyback of 50 million to 100 million yuan [34] - The company specializes in the production and development of metallurgical products [35] Group 20 - Company Fujia plans to repurchase shares worth 15 million to 30 million yuan [36] - The company focuses on smart cleaning appliances and key components [37] Group 21 - Company Mould Technology received a project designation letter for exterior parts from a luxury car client, with an estimated total sales of 2.07 billion yuan [38] - The project is expected to start mass production in April 2027 [38] Group 22 - Company Longxin General expects a net profit of 4.55 billion to 5.30 billion yuan for Q1 2025, a year-on-year increase of 76.65% to 105.77% [39] - The company specializes in motorcycles, engines, and general machinery products [40] Group 23 - Company Dongfang Securities reported a net profit of 1.436 billion yuan for Q1 2025, a year-on-year increase of 62.08% [41] - The company focuses on investment management and securities trading [42] Group 24 - Company Yalian Machinery plans to use up to 800 million yuan of idle funds for low-risk financial products [43] - The company specializes in the production of engineered wood production lines and equipment [44] Group 25 - Company Guanghua Technology reported a net loss of 205 million yuan for 2024, with total revenue of 2.589 billion yuan [45] - The company focuses on PCB chemicals and lithium battery materials [46] Group 26 - Company Boya Biotechnology plans to publicly transfer 80% of its subsidiary's equity for 213 million yuan [47] - The transaction aims to optimize resource allocation focusing on blood products [48] Group 27 - Company Darui Electronics plans to repurchase shares worth 30 million to 50 million yuan [49] - The company specializes in customized components and automation equipment [50] Group 28 - Company Hongying Intelligent plans to repurchase shares worth 30 million to 40 million yuan [51] - The company focuses on smart control products and assemblies [52] Group 29 - Company Guangku Technology announced a change in the upper shareholding structure of its controlling shareholder [53] - The operational activities of the company will not be materially affected [54] Group 30 - Company Dingjie Smart's application for convertible bond issuance has been accepted by the Shenzhen Stock Exchange [55] - The company provides digital and intelligent solutions for various industries [56]

英思特（301622）公告，2024年营业收入11.85亿元，同比增长24.45%。归属于上市公司股东的净利润 1.77亿元，同比增长28.15%。基本每股收益2.04元/股，同比增长28.30%。公司拟向全体股东每10股派发 现金红利1.2元(含税)，送红股0股(含税)，以资本公积金向全体股东每10股转增0股。 ...

一、本次追加使用部分闲置自有资金进行现金管理的基本情况 （一）现金管理目的 核查意见 华泰联合证券有限责任公司 关于包头市英思特稀磁新材料股份有限公司 使用部分闲置自有资金进行现金管理的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐人"）作 为包头市英思特稀磁新材料股份有限公司（以下简称"英思特"或"公司"）首 次公开发行股票并在创业板上市持续督导阶段的保荐人，根据《证券发行上市保 荐业务管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市 公司自律监管指引第 2 号——创业板上市公司规范运作》及《深圳证券交易所上 市公司自律监管指引第 13 号——保荐业务》等有关规定，对英思特拟追加使用 部分闲置自有资金进行现金管理事项进行了尽职调查，具体核查情况如下： 为提高闲置自有资金使用效率，对暂时闲置自有资金进行现金管理，以增加 资金收益，为公司和股东谋取较好的投资回报。 （二）额度及期限 公司本次在原有人民币 3.5 亿元（含本数）自有资金现金管理额度的基础上， 追加使用不超过人民币 1.5 亿元（含本数）闲置自有资金进行现金管理，增加后 公司及其子公司拟使用不超过人民币 5 ...

华泰联合证券有限责任公司 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于同意包头市英思特稀磁新材料股份有限公 司首次公开发行股票注册的批复》（证监许可[2024]1376 号）核准，公司于 2024 年 11 月 22 日首次公开发行人民币普通股（A 股）2,898.297 万股，每股发行价 为 22.36 元，募集资金总额为人民币 64,805.92 万元，扣除发行费用（不含税） 人民币 7,747.67 万元后，实际募集资金净额为人民币 57,058.25 万元。该募集资 金已于 2024 年 11 月 28 日到账。上述募集资金已于 2024 年 11 月 28 日划至公司 指定账户，容诚会计师事务所（特殊普通合伙）已于 2024 年 11 月 28 日对本次 发行的募集资金到位情况进行了审验，并出具了《验资报告》（容诚验字 [2024]230Z0125 号）。公司对募集资金采取了专户存储管理。 （二）募集资金使用及结余情况 截至 2024 年 12 月 31 日止，公司募集资金使用及结余情况如下： 1 关于包头市英思特稀磁新材料股份有限公司 2024年度募集 ...

审计报告 包头市英思特稀磁新材料股份有限公司 容诚审字[2025]230Z0127 号 容诚会计师事务所(特殊普通合伙) 中国·北京 目 录 | 序号 | 内 容 | 页码 | | --- | --- | --- | | 1 | 审计报告 | 1-6 | | 2 | 合并资产负债表 | 1 | | 3 | 合并利润表 | 2 | | 4 | 合并现金流量表 | 3 | | 5 | 合并所有者权益变动表 | 4 | | 6 | 母公司资产负债表 | 5 | | 7 | 母公司利润表 | 6 | | 8 | 母公司现金流量表 | 7 | | 9 | 母公司所有者权益变动表 | 8 | | 10 | 财务报表附注 | 9-106 | 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 审 计 报 告 容诚审字[2025]230Z0127 号 ...

中国·北京 内部控制审计报告 包头市英思特稀磁新材料股份有限公司 容诚审字[2025]230Z0128 号 容诚会计师事务所(特殊普通合伙) 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 内部控制审计报告 容诚审字[2025]230Z0128 号 包头市英思特稀磁新材料股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了包头市英思特稀磁新材料股份有限公司（以下简称英思特）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是英思 特董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部 ...

包头市英思特稀磁新材料股份有限 公司 章 程 中国·包头 二〇二五年四月 | | | | 第一章 总 则 | 1 | | --- | --- | | 第二章 | 经营宗旨和经营范围 2 | | 第三章 | 股份 2 | | 第一节 | 股份发行 2 | | 第二节 | 股份增减和回购 3 | | 第三节 | 股份转让 4 | | 第四章 | 股东和股东会 5 | | 第一节 | 股东 5 | | 第二节 | 股东会的一般规定 7 | | 第三节 | 股东会的召集 11 | | 第四节 | 股东会的提案与通知 12 | | 第五节 | 股东会的召开 14 | | 第六节 | 股东会的表决和决议 16 | | 第五章 | 董事会 22 | | 第一节 | 董事 22 | | 第二节 | 董事会 26 | | 第六章 | 总经理及其他高级管理人员 34 | | 第七章 | 监事会 36 | | 第一节 | 监事 36 | | 第二节 | 监事会 37 | | 第八章 | 财务会计制度、利润分配和审计 38 | | 第一节 | 财务会计制度 38 | | 第二节 | 内部审计 41 | | 第三节 | 会计师事务所的 ...

包头市英思特稀磁新材料股份有限公司 独立董事2 0 2 4年度述职报告 （常江） 2024 年度，本人作为包头市英思特稀磁新材料股份有限公司（以下简称"公 司"）的独立董事，严格按照《中华人民共和国公司法》（以下简称"《公司法》"） 《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》《深圳 证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律 法规及《公司章程》《独立董事工作制度》等公司相关规定和要求，忠实履行独 立董事的职责，充分发挥独立董事参与决策、监督制衡和专业咨询的作用，维护 上市公司整体利益，保护中小股东合法权益。现将本人 2024 年度工作情况汇报 如下： 一、独立董事的基本情况 （二）独立性说明 在担任公司独立董事期间，本人未在公司担任除独立董事以外的任何职务， 也未在公司主要股东公司担任任何职务，不存在任何可能妨碍其进行独立客观判 断的关系，不存在影响独立董事独立性的情况。本人符合《上市公司独立董事管 理办法》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》等法律法规及《公司章程》中关于独立董事的任职资格及独立性的相 关要求。 ...